Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NRX Pharmaceuticals (NRXP) Cash from Financing Activities (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Cash from Financing Activities for 2 consecutive years, with $4.6 million as the latest value for Q4 2025.

Quarterly Cash from Financing Activities rose 141.42% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.3 million through Dec 2025, up 210.97% year-over-year, with the annual reading at $23.3 million for FY2025, 210.97% up from the prior year.
Cash from Financing Activities for Q4 2025 was $4.6 million at NRX Pharmaceuticals, down from $9.7 million in the prior quarter.
The five-year high for Cash from Financing Activities was $9.7 million in Q3 2025, with the low at $395000.0 in Q1 2024.